SCHEMBL13305324

SCHEMBL13305324

Bc1cnn2c(NCc3ccc(-c4csnn4)cc3)cc(C3CCNCC3)nc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 4/20 0.51
▸ CDK2 P24941 7/20 0.43
▸ CHEK1 O14757 5/20 0.43
▸ CCNA2 P20248 1/20 0.43
▸ CCNA1 P78396 1/20 0.43
▸ CCNE1 P24864 4/20 0.38
▸ CDK1 P06493 3/20 0.38
▸ CDK7 P50613 3/20 0.38
▸ CCNH P51946 3/20 0.38
▸ MNAT1 P51948 3/20 0.38
▸ PDE10A Q9Y233 1/20 0.35
▸ MPO P05164 1/20 0.34
▸ CDK4 P11802 2/20 0.34
▸ CDK9 P50750 2/20 0.34
▸ CDK6 Q00534 2/20 0.34
▸ CDK5 Q00535 2/20 0.34
▸ CDK8 P49336 1/20 0.34
▸ AKT1 P31749 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12952915 0.90 GSK3B (0.64) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL12954197 0.81 GSK3B (0.63) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL13304620 0.80 GSK3B (0.50) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL13305680 0.80 GSK3B (0.55) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL13146410 0.78 GSK3B (0.79) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL13146206 0.77 GSK3B (0.51) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL13305099 0.77 GSK3B (0.57) GSK3BCDK2CCNA2CCNA1CCNE1
SCHEMBL13305175 0.74 GSK3B (0.48) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL24791650 0.73 GSK3B (0.56) GSK3BCDK2CHEK1CCNA2CCNA1
SCHEMBL13118710 0.71 GSK3B (0.44) GSK3BCDK2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537116-B1 PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES SCHERING CORP (US) 2010-06-02 — — EP disclosed
Send feedback